Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 10/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.36 |
| ▸ | BRD9 | Q9H8M2 | 6/20 | 0.36 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.35 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.35 |
| ▸ | BRD7 | Q9NPI1 | 2/20 | 0.34 |
| ▸ | BRD2 | P25440 | 1/20 | 0.34 |
| ▸ | PDE4A | P27815 | 1/20 | 0.34 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.34 |
| ▸ | BPTF | Q12830 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16651614 | 1.00 | BRD4 (0.44) | BRD4PDE4BBRD9TLR8CREBBP | |
| SCHEMBL16651731 | 0.94 | BRD4 (0.46) | BRD4PDE4BBRD9CREBBPBRD7 | |
| SCHEMBL16651403 | 0.86 | BRD4 (0.53) | BRD4BRD9CREBBP | |
| SCHEMBL29848844 | 0.86 | BRD4 (0.53) | BRD4BRD9CREBBP | |
| SCHEMBL16650991 | 0.85 | BRD4 (0.43) | BRD4PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL29848752 | 0.85 | BRD4 (0.43) | BRD4PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL29848815 | 0.84 | BRD4 (0.40) | BRD4 | |
| SCHEMBL16651256 | 0.84 | BRD4 (0.40) | BRD4 | |
| SCHEMBL16651201 | 0.83 | CREBBP (0.37) | BRD4PDE4BCREBBPPDE4APDE4C | |
| SCHEMBL29848696 | 0.83 | CREBBP (0.37) | BRD4PDE4BCREBBPPDE4APDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240182490-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2024-06-06 | — | — | US | disclosed |
| US-11884680-B2 | Bromodomain inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2024-01-30 | — | — | US | disclosed |
| US-20220315601-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2022-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240182490-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | BRD4 5/4885PDE4B 2787/4885BRD9 19/4885 |
| US-20220315601-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | BRD4 5/4885PDE4B 2787/4885BRD9 19/4885 |
| US-11884680-B2 | Bromodomain inhibitors | BRD3, EP300, BRPF3 | BRD4 5/4885PDE4B 2787/4885BRD9 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.